• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?印度的雌激素受体阴性乳腺癌：我们在这种亚型上的负担真的更重吗？
Indian J Surg Oncol. 2011 Jun;2(2):122-5. doi: 10.1007/s13193-011-0072-8. Epub 2011 May 31.
2
ER-/PR+ breast cancer: A distinct entity, which is morphologically and molecularly close to triple-negative breast cancer.雌激素受体-/孕激素受体阳性乳腺癌：一种独特的实体，在形态学和分子上与三阴性乳腺癌接近。
Int J Cancer. 2021 Jul 1;149(1):200-213. doi: 10.1002/ijc.33539. Epub 2021 Mar 18.
3
Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in New Delhi, India.印度新德里一家三级护理医院乳腺癌患者的免疫组织化学特征
Asian Pac J Cancer Prev. 2015;16(12):4959-64. doi: 10.7314/apjcp.2015.16.12.4959.
4
Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.使用定量氟-18氟脱氧葡萄糖/正电子发射断层扫描成像参数比较三阴性乳腺癌与雌激素受体阳性/孕激素受体阳性/人表皮生长因子受体2阴性乳腺癌：一种对疾病特征描述可能有用的方法。
Cancer. 2008 Mar 1;112(5):995-1000. doi: 10.1002/cncr.23226.
5
Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. a single institution survey spanning 1998 to 2010.根据激素受体和 Her2 免疫组化确定的不同肿瘤亚型，乳腺癌患者的生存和临床病理特征。一项跨越 1998 年至 2010 年的单机构调查。
Breast. 2012 Jun;21(3):366-73. doi: 10.1016/j.breast.2012.03.004. Epub 2012 Apr 7.
6
Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status.乳腺癌患者的病前体重及其与原发肿瘤直径的关系；其对雌激素和孕激素受体状态的依赖性。
Breast Cancer Res Treat. 2001 Jul;68(2):159-69. doi: 10.1023/a:1011977118921.
7
Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.雌激素或孕激素受体阴性表达在腔面B型HER2阴性乳腺癌患者中的预后价值
World J Surg Oncol. 2016 Sep 13;14(1):244. doi: 10.1186/s12957-016-0999-x.
8
Identification of an immune-suppressed subtype of feline triple-negative basal-like invasive mammary carcinomas, spontaneous models of breast cancer.鉴定猫三阴性基底样浸润性乳腺癌的免疫抑制亚型，即乳腺癌的自发模型。
Tumour Biol. 2020 Jan;42(1):1010428319901052. doi: 10.1177/1010428319901052.
9
Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.通过SUVmax、SUVavg、代谢肿瘤体积和总病变糖酵解描述的18F-FDG摄取值与乳腺癌临床病理预后因素及生物学亚型的相关性。
Nucl Med Commun. 2015 Jan;36(1):28-37. doi: 10.1097/MNM.0000000000000217.
10
Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience.南印度乳腺癌患者的激素受体状态（雌激素受体、孕激素受体）、人表皮生长因子-2及p53：一家三级护理中心的经验
Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):117-22. doi: 10.4103/0971-5851.158844.

引用本文的文献

1
Breast Carcinoma - A Comparative Study of Immunohistochemistry and Fluorescence in Situ Hybridization for Her-2 Assessment and Association of ER, PR, HER-2 and Ki-67 Expression with Clinico-Pathological Parameters.乳腺癌——免疫组织化学与荧光原位杂交检测Her-2的比较研究以及雌激素受体、孕激素受体、Her-2和Ki-67表达与临床病理参数的相关性
Iran J Pathol. 2022 Fall;17(4):435-442. doi: 10.30699/IJP.2022.538167.2712. Epub 2022 Sep 2.
2
Clinicopathological Characteristics and Prognosis of Breast Cancer in Young Women - A Single Center Study in a Developing Country.年轻女性乳腺癌的临床病理特征及预后——发展中国家的一项单中心研究
Cancer Manag Res. 2021 Feb 17;13:1601-1607. doi: 10.2147/CMAR.S299066. eCollection 2021.
3
Meta-Analysis of Prevalence of Triple-Negative Breast Cancer and Its Clinical Features at Incidence in Indian Patients With Breast Cancer.印度乳腺癌患者三阴性乳腺癌发病率及其临床特征的Meta分析
JCO Glob Oncol. 2020 Jul;6:1052-1062. doi: 10.1200/GO.20.00054.
4
Low serum 25-hydroxy vitamin D levels are associated with aggressive breast cancer variants and poor prognostic factors in patients with breast carcinoma.血清25-羟基维生素D水平低与侵袭性乳腺癌亚型及乳腺癌患者的不良预后因素相关。
Arch Endocrinol Metab. 2018 Aug;62(4):452-459. doi: 10.20945/2359-3997000000062.
5
Patterns of Care of Breast Cancer Patients in a Rural Cancer Center in Western India.印度西部一家农村癌症中心乳腺癌患者的护理模式
Indian J Surg Oncol. 2018 Sep;9(3):374-380. doi: 10.1007/s13193-018-0748-4. Epub 2018 Apr 11.
6
Estrogen receptor, Progesterone receptor, and human epidermal growth factor receptor-2 status in breast cancer: A retrospective study of 5436 women from a regional cancer center in South India.乳腺癌中雌激素受体、孕激素受体及人表皮生长因子受体2状态：对印度南部一家地区癌症中心5436名女性的回顾性研究
South Asian J Cancer. 2018 Jan-Mar;7(1):7-10. doi: 10.4103/sajc.sajc_211_17.
7
Improving accuracy of breast cancer biomarker testing in India.提高印度乳腺癌生物标志物检测的准确性。
Indian J Med Res. 2017 Oct;146(4):449-458. doi: 10.4103/ijmr.IJMR_896_16.
8
Hormone-receptor expression and survival patterns in operated cases of female invasive ductal breast carcinoma in Kerala: a retrospective cohort study.喀拉拉邦女性浸润性导管乳腺癌手术病例中的激素受体表达及生存模式：一项回顾性队列研究
World J Surg Oncol. 2015 Apr 23;13:160. doi: 10.1186/s12957-015-0582-x.
9
Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal.通过筛查和/或早期检测在低收入和中等收入国家预防乳腺癌：现实与超现实。
World J Clin Oncol. 2014 Aug 10;5(3):509-19. doi: 10.5306/wjco.v5.i3.509.
10
Estrogen and progesterone receptor status in breast cancer: a cross-sectional study of 450 women in Kerala, South India.乳腺癌中雌激素和孕激素受体状态：印度南部喀拉拉邦450名女性的横断面研究。
World J Surg Oncol. 2014 Apr 24;12:120. doi: 10.1186/1477-7819-12-120.

本文引用的文献

1
Risk factors according to estrogen receptor status of breast cancer patients in Trivandrum, South India.印度南部特里凡得琅市乳腺癌患者雌激素受体状态的风险因素
Int J Cancer. 2009 Oct 1;125(7):1663-70. doi: 10.1002/ijc.24460.
2
Hormone receptors over the last 8 years in a cancer referral center in India: what was and what is?印度一家癌症转诊中心过去8年的激素受体情况：过去怎样，现在如何？
Indian J Pathol Microbiol. 2009 Apr-Jun;52(2):171-4. doi: 10.4103/0377-4929.48909.
3
Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India.印度南部一家社区医院浸润性乳腺癌的流行病学及治疗模式
World J Surg Oncol. 2007 May 23;5:56. doi: 10.1186/1477-7819-5-56.
4
High incidence of oestrogen receptor negative progesterone receptor positive phenotype in Indian breast cancer: fact or fiction?印度乳腺癌中雌激素受体阴性孕激素受体阳性表型的高发生率：事实还是虚构？
Indian J Pathol Microbiol. 2005 Apr;48(2):199-201.
5
Clinical features and prognostic factors of early breast cancer at a major cancer center in North India.印度北部一家主要癌症中心早期乳腺癌的临床特征及预后因素
Indian J Cancer. 2005 Jan-Mar;42(1):40-5. doi: 10.4103/0019-509x.15099.
6
Comparison of immunoexpression of 2 antibodies for estrogen receptors (1D5 and 6F11) in breast carcinomas using different antigen retrieval and detection methods.
Appl Immunohistochem Mol Morphol. 2004 Jun;12(2):177-82. doi: 10.1097/00129039-200406000-00014.
7
Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures?
Appl Immunohistochem Mol Morphol. 2004 Mar;12(1):8-13. doi: 10.1097/00129039-200403000-00002.
8
Hormone receptor status of breast cancer in India: a study of 798 tumours.印度乳腺癌的激素受体状态：798例肿瘤的研究
Breast. 2000 Oct;9(5):267-70; discussion 270. doi: 10.1054/brst.2000.0134.
9
Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma.浸润性乳腺癌雌激素受体免疫组化染色结果一致时所需的最短福尔马林固定时间。
Am J Clin Pathol. 2003 Jul;120(1):86-92. doi: 10.1309/QPHD-RB00-QXGM-UQ9N.
10
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.美国国立卫生研究院共识发展会议声明：乳腺癌辅助治疗，2000年11月1日至3日
J Natl Cancer Inst. 2001 Jul 4;93(13):979-89. doi: 10.1093/jnci/93.13.979.

印度的雌激素受体阴性乳腺癌：我们在这种亚型上的负担真的更重吗？

Estrogen Receptor Negative Breast Cancer in India: Do We Really Have Higher Burden of this Subtype?

作者信息

Manjunath Suraj, Prabhu Jyothi S, Kaluve Rohini, Correa Marjorie, Sridhar T S

出版信息

Indian J Surg Oncol. 2011 Jun;2(2):122-5. doi: 10.1007/s13193-011-0072-8. Epub 2011 May 31.

DOI:10.1007/s13193-011-0072-8
PMID:22693404
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3244189/
Abstract

ER negative and Triple negative breast cancers carry a poorer prognosis and are not amenable to hormone therapy. It has been previously observed that Indian patients with breast cancer have a higher tendency to have these tumours. Whether this is due to inherent biological differences in the tumours of our patients is a matter of much debate. We have analysed 250 patients of breast cancer for hormone receptor status, compared them with western series, and attempted to support the hypothesis that the higher ER negativity and triple negativity is indeed due to different tumour biology.

摘要

雌激素受体阴性和三阴性乳腺癌的预后较差，且不适合接受激素治疗。此前已有观察发现，印度乳腺癌患者患这些肿瘤的倾向更高。这是否归因于我们患者肿瘤中固有的生物学差异，是一个备受争议的问题。我们分析了250例乳腺癌患者的激素受体状态，将其与西方系列研究进行比较，并试图支持以下假设：雌激素受体阴性率和三阴性率较高确实是由于不同的肿瘤生物学特性所致。